Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease

Li,Tao; Yao,Weina

doi:10.3892/etm.2018.6669

Therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease

Authors:
- Tao Li
- Weina Yao
View Affiliations

Affiliations: Emergency Center, Jinan Zhangqiu District Hospital of TCM, Jinan, Shandong 250200, P.R. China, Department of Cardiovascular Medicine, The First People's Hospital of Jinan, Jinan, Shandong 250000, P.R. China
Published online on: August 30, 2018 https://doi.org/10.3892/etm.2018.6669
Pages: 4119-4123
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to investigate the therapeutic effect of irbesartan combined with atorvastatin calcium in the treatment of rats with coronary heart disease. One hundred sixty Wistar rats were selected to establish coronary heart disease model. Rats with coronary heart disease were randomly divided into 4 groups: Model, irbesartan, atorvastatin calcium and combination groups (irbesartan combined with atorvastatin calcium group). Rats in irbesartan group were treated with 50 mg/(kg.day) irbesartan; rats in atorvastatin calcium group were given atorvastatin calcium at a dose of 10 mg/(kg.day); rats in combination group were subjected to atorvastatin calcium at a dose of 10 mg/(kg.day) and irbesartan at a dose of 50 mg/(kg.day), while rats in model groups were given intragastric administration of normal saline at a dose of 2 ml/day. Serum lipids, including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and TC/HDL-C, were measured by automatic biochemical analyzer. Expression of sPLA2-V in myocardium and aortic trunk of rats was detected by reverse transcription-PCR (RT-PCR) and western blot analysis. After treatment, levels of serum TC, TG, LDL-C, HDL-C and TC/HDL-C in rats of each treatment group were better than those in model group (p<0.05). Expression level of sPLA2-Ⅴ in myocardium and aortic trunk in model group was significantly higher than that in other groups (p<0.05). Expression level of sPLA2-Ⅴ in combination group was significantly lower than that in irbesartan and atorvastatin calcium groups (p<0.05). Combination of irbesartan and atorvastatin calcium is superior to irbesartan or atorvastatin calcium alone in the treatment of rats with coronary heart disease. The possible explanation is that the two drugs can reduce the expression of sPLA2-V in myocardium and aortic trunk, which in turn relieved atherosclerosis and achieved better therapeutic effect.

View Figures

View References

1	Wang EY, Dixson J, Schiller NB and Whooley MA: Causes and predictors of death in patients with coronary heart disease (from the heart and soul study). Am J Cardiol. 119:27–34. 2017. View Article : Google Scholar : PubMed/NCBI
2	Woods SE: Primary prevention of coronary heart disease in women. Should asymptomatic women 50 years of age take aspirin regularly? Arch Fam Med. 3:361–364. 1994. View Article : Google Scholar : PubMed/NCBI
3	Menotti A, Puddu PE, Adachi H, Kafatos A, Tolonen H and Kromhout D: The strength of the multivariable associations of major risk factors predicting coronary heart disease mortality is homogeneous across different areas of the Seven Countries Study during 50-year follow-up. Acta Cardiol. 8:1–7. 2017.
4	Brown JP, Clark AM, Dalal H, Welch K and Taylor RS: Patient education in the contemporary management of coronary heart disease. Cochrane Database Syst Rev. 2010:CD0088952010.PubMed/NCBI
5	Lebwohl B, Cao Y, Zong G, Hu FB, Green PHR, Neugut AI, Rimm EB, Sampson L, Dougherty LW, Giovannucci E, et al: Long term gluten consumption in adults without celiac disease and risk of coronary heart disease: Prospective cohort study. BMJ. 357:j18922017. View Article : Google Scholar : PubMed/NCBI
6	Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG and Howard BV: Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: The strong heart study. Diabetes Care. 40:529–537. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lu W, Zhu Y, Han Z, Wang X, Wang X and Qiu C: Drug-coated balloon in combination with bare metal stent strategy for de novo coronary artery disease: A PRISMA-compliant meta-analysis of randomized clinical trials. Medicine (Baltimore). 96:e63972017. View Article : Google Scholar : PubMed/NCBI
8	Serban MC, Muntner P and Rosenson RS: Reply: Statin intolerance and risk for recurrent myocardial infarction, Coronary heart disease events, and all-cause mortality. J Am Coll Cardiol. 70:685–686. 2017. View Article : Google Scholar : PubMed/NCBI
9	Wiklund O, Mattsson-Hultén L, Hurt-Camejo E and Oscarsson J: Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 251:338–347. 2002. View Article : Google Scholar : PubMed/NCBI
10	Zhao Y, Peng R, Zhao W, Liu Q, Guo Y, Zhao S and Xu D: Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease. Medicine (Baltimore). 96:e61042017. View Article : Google Scholar : PubMed/NCBI
11	Ricci F, De Caterina R and Fedorowski A: Orthostatic hypotension: Epidemiology, prognosis, and treatment. J Am Coll Cardiol. 66:848–860. 2015. View Article : Google Scholar : PubMed/NCBI
12	Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL and Chen JH: Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J. 24:1824–1832. 2003. View Article : Google Scholar : PubMed/NCBI
13	Holmes MV, Exeter HJ, Folkersen L, Nelson CP, Guardiola M, Cooper JA, Sofat R, Boekholdt SM, Khaw KT, Li KW, et al: CARDIoGRAM Consortium: Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: Modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet. 7:144–150. 2014. View Article : Google Scholar : PubMed/NCBI
14	Dickson Vaughan V, Lee CS, Yehle KS, Mola A, Faulkner KM and Riegel B: Psychometric testing of the Self-Care of coronary heart disease inventory (SC-CHDI). Res Nurs Health. 40:15–22. 2017. View Article : Google Scholar : PubMed/NCBI
15	Huang L, Zheng Y, Yuan X, Ma Y, Xie G, Wang W, Chen H and Shen L: Decreased frequencies and impaired functions of the CD31⁺ subpopulation in T_reg cells associated with decreased FoxP3 expression and enhanced Treg cell defects in patients with coronary heart disease. Clin Exp Immunol. 187:441–454. 2017. View Article : Google Scholar : PubMed/NCBI
16	Tang SS, Xu S, Cheng J, Cai MY, Chen L, Liang LL, Yang XL, Chen C, Liu XG and Xiong XD: Two tagSNPs rs352493 and rs3760908 within SIRT6 gene are associated with the severity of coronary artery disease in a chinese han population. Dis Markers. 2016:16280412016. View Article : Google Scholar : PubMed/NCBI
17	McLaren JE, Michael DR, Ashlin TG and Ramji DP: Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res. 50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
18	Wu G, Li GB and Dai B: Association of KIF6 variant with lipid level and angiographic coronary artery disease events risk in the Han Chinese population. Molecules. 17:11269–11280. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ntekim OE, Allard JS, Ngwa JS, Johnson AA, Castor C, Iyalomhe O, Fungwe TV, Ntekim CC and Obisesan T: Additive effects of capsaicin oleoresin, irbesartan and amlodipine besylate on the blood pressure of spontaneously hypertensive rats. J Med Plants Res. 10:468–478. 2016. View Article : Google Scholar
20	Strupp M: The results support the use of atorvastatin in elderly patients with recent stroke or TIA. Neurology. 73:8172009. View Article : Google Scholar : PubMed/NCBI
21	Xin H, Chen ZY, Lv XB, Liu S, Lian ZX and Cai SL: Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction. Eur Rev Med Pharmacol Sci. 17:999–1004. 2013.PubMed/NCBI
22	Burstein B and Nattel S: Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 51:802–809. 2008. View Article : Google Scholar : PubMed/NCBI
23	Rivard L and Khairy P: Mechanisms, clinical significance, and prevention of cognitive impairment in patients with atrial fibrillation. Can J Cardiol. 33:1556–1564. 2017. View Article : Google Scholar : PubMed/NCBI
24	Ikonomidis I and Michalakeas CA: Phospholipases in cardiovascular diseaseAdvances in Biochemistry in Health and Disease: Phospholipases in Health and Disease. Tappia PS and Dhalla NS: 10. Springer; New York: pp. 73–83. 2014
25	Divchev D, Grothusen C, Luchtefeld M, Thoenes M, Onono F, Koch R, Drexler H and Schieffer B: Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease. Eur Heart J. 29:1956–1965. 2008. View Article : Google Scholar : PubMed/NCBI